Three independent discounted-cash-flow-style models value Atea Pharmaceuticals, Inc. Common Stock every trading day. 3 of 3 currently price AVIR above its market price.
| Free Cash Flow model | $31.89 |
| Excess Profit model | $26.53 |
| Residual Earnings model | $13.98 |
| Dividend Discount model | — |
| Piotroski F-Score | 2 / 4 |
| Return on invested capital | +15.3% |
| Net debt / EBITDA | -0.6× |
| Gross margin | +100.0% |
| Revenue CAGR | — |
| Cash conversion | -0.7× |
| Dividend yield | — |
| Buyback yield | — |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open AVIR in StockKitty